Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2012 Feb;12(1):70-5.
doi: 10.1007/s11910-011-0236-5.

Enzyme replacement therapy for Pompe disease

Corrado Angelini  1 , Claudio Semplicini
Affiliations
Review

Enzyme replacement therapy for Pompe disease

Corrado Angelini et al. Curr Neurol Neurosci Rep. 2012 Feb.

Abstract

Late-onset glycogenosis type II (glycogen storage disease type II [GSDII]) is a rare autosomal disorder caused by deficiency of acid maltase, a lysosomal enzyme that hydrolyzes glycogen to glucose. Recently, both infantile and adult GSDII patients have been treated with enzyme replacement therapy (ERT), and a number of studies including large cohorts of GSDII patients have recently demonstrated that ERT is effective in modifying the natural course of the disease. The opportunity of this new treatment gave new hope to patients, but also an important impulse to the research on every feature of the disease, leading to a deeper knowledge on the response to treatment, on clinical manifestations, and on pathophysiologic aspects such as the role of autophagy and immune status.

PubMed Disclaimer

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. J Child Neurol. 2007 May;22(5):565-73 - PubMed
    1. Neurology. 2004 Nov 9;63(9):1688-92 - PubMed
    1. J Pediatr. 2011 Jun;158(6):1023-1027.e1 - PubMed
    1. Neurology. 2008 Dec 2;71(23 Suppl 2):S12-36 - PubMed
    1. Appl Physiol Nutr Metab. 2009 Oct;34(5):817-28 - PubMed

Publication types

MeSH terms

LinkOut - more resources